Holen Sie sich die Stockscreener-App
12.93
7.64%
-1.07
Schlusskurs vom Vortag:
$14.00
Offen:
$13.91
24-Stunden-Volumen:
1.12M
Relative Volume:
1.17
Marktkapitalisierung:
$832.11M
Einnahmen:
$22.39M
Nettoeinkommen (Verlust:
$-221.04M
KGV:
-3.4811
EPS:
-3.7143
Netto-Cashflow:
$-178.65M
1W Leistung:
-16.74%
1M Leistung:
-37.32%
6M Leistung:
-12.28%
1J Leistung:
+47.94%
1-Tages-Spanne:
$12.81
$13.91
1-Wochen-Bereich:
$12.81
$15.64
52-Wochen-Spanne:
$6.7318
$23.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
12.93 | 832.11M | 22.39M | -221.04M | -178.65M | -3.7143 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Eingeleitet | Citigroup | Buy |
| 2026-02-02 | Eingeleitet | Guggenheim | Buy |
| 2025-08-21 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-06-11 | Fortgesetzt | Stifel | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Ellsworth Advisors LLC Buys New Stake in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Form 8K Cullinan Therapeutics, Inc For: 2 October By Investing.com - Investing.com South Africa
Up to $100M hinges on first-line approval as Cullinan (CGEM) starts a lung cancer drug submission. - Stock Titan
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Has Consensus Price Target of $33.71 According to Analysts - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance UK
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program - GlobeNewswire Inc.
Cullinan Therapeutics (NASDAQ:CGEM) Given "Buy" Rating at BTIG Research - MarketBeat
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases - Seeking Alpha
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance Australia
510,325 Shares in Cullinan Therapeutics, Inc. $CGEM Purchased by Bank of America Corp DE - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 7.1%Here's What Happened - MarketBeat
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - GlobeNewswire Inc.
Cullinan Therapeutics (NasdaqGS:CGEM) Stock Price - Simply Wall Street
Cullinan Therapeutics, Inc. (CGEM) Stock Analysis: Potential Upside of Over 57% Ignites Investor Interest - DirectorsTalk Interviews
Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Lowered to Sell Rating by Wall Street Zen - MarketBeat
EGFR-NSCLC Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innova - Barchart.com
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - Investing News Network
Cullinan Therapeutics to Present Phase 3 REZILIENT3 Interim Data on Zipalertinib Plus Chemotherapy at WCLC 2026, Host Investor Event - Quiver Quantitative
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - The Manila Times
Cullinan Therapeutics to Host Virtual Analyst and Investor - GlobeNewswire
Cullinan Therapeutics CSO Jennifer Michaelson Executes 8,000 Share Sale Under 10b5-1 Plan - Kalkine Media
Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics (CGEM) insider sells 8,000 shares under pre-arranged plan - Stock Titan
171,031 Shares in Cullinan Therapeutics, Inc. $CGEM Bought by Bank of New York Mellon Corp - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Corient Private Wealth LP Takes $970,000 Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
The Manufacturers Life Insurance Company Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
CGEM Should I Buy - Intellectia AI
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded to Hold at Wall Street Zen - MarketBeat
Moore Capital Management LP Raises Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Algert Global LLC Sells 72,880 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
BlackRock Inc. Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - marketbeat.com
Connor Clark & Lunn Investment Management Ltd. Takes Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Elmind Capital LP Purchases New Shares in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Boone Capital Management LLC Makes New Investment in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics shows strong multi-asset pipeline with key drug milestones boosting funding prospects. - Pluang
Bank of America Corp DE Acquires 170,417 Shares of Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Deutsche Bank AG Purchases Shares of 382,840 Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Cullinan (CGEM) Quarterly Figures: Reported EPS Tops Expectations at the Close; After Results: The Share Price Adds 0.65% in the Latest SessionEarnings Yield Analysis - vinanet.vn
Cullinan (CGEM) Quarterly Figures: Reported EPS Tops Expectations at the Close; After Results: The Share Price Adds 0.65% in the Latest SessionCapex Guidance - vinanet.vn
Blue Owl Capital Holdings LP Invests $28.04 Million in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Tokyo’s Taiho and Cullinan Announce Positive Phase 3 Lung Cancer Results - geneonline.com
Is Cullinan Therapeutics (CGEM) Fully Valued After Its Phase 3 Trial Win? - simplywall.st
Taiho, Cullinan trial results selected for lung cancer conference By Investing.com - Investing.com Australia
Cullinan Therapeutics (CGEM) to Present Phase 3 REZILIENT3 Trial - GuruFocus
Taiho, Cullinan trial results selected for lung cancer conference - Investing.com
Taiho, Cullinan trial results selected for lung cancer conference By Investing.com - Investing.com India
Taiho, Cullinan trial results selected for lung cancer conference By Investing.com - Investing.com UK
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cullinan Therapeutics Inc-Aktie (CGEM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer |
Sep 08 '26 |
Sale |
21.57 |
8,000 |
172,560 |
158,844 |
| JENNIFER MICHAELSON | Officer |
Sep 08 '26 |
Proposed Sale |
22.09 |
8,000 |
176,720 |
0 |
| JENNIFER MICHAELSON | Officer |
Aug 13 '26 |
Proposed Sale |
19.60 |
30,000 |
588,000 |
0 |
| Michaelson Jennifer | Chief Scientific Officer |
Aug 13 '26 |
Option Exercise |
4.30 |
30,000 |
129,000 |
192,844 |
| Michaelson Jennifer | Chief Scientific Officer |
Aug 13 '26 |
Sale |
20.26 |
30,000 |
607,800 |
162,844 |
| Michaelson Jennifer | Chief Scientific Officer |
Jul 06 '26 |
Sale |
17.82 |
8,000 |
142,560 |
162,844 |
| JENNIFER MICHAELSON | Officer |
Jul 06 '26 |
Proposed Sale |
17.63 |
8,000 |
141,040 |
0 |
| Michaelson Jennifer | Chief Scientific Officer |
Jul 06 '26 |
Option Exercise |
4.30 |
4,000 |
17,200 |
170,844 |
| Michaelson Jennifer | Chief Scientific Officer |
May 05 '26 |
Option Exercise |
4.30 |
4,000 |
17,200 |
174,844 |
| Michaelson Jennifer | Chief Scientific Officer |
May 05 '26 |
Sale |
14.62 |
8,000 |
116,996 |
166,844 |
3.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):